Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.39USD
18 Jul 2018
Change (% chg)

$-0.01 (-0.71%)
Prev Close
$1.40
Open
$1.40
Day's High
$1.40
Day's Low
$1.37
Volume
358,415
Avg. Vol
1,252,187
52-wk High
$2.75
52-wk Low
$0.91

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $338.31
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

  NVAX.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -0.77 -- --
ROI: -57.83 2.21 14.61
ROE: -829.23 3.85 16.34

BRIEF-Novavax Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Novavax Reports Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019

* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE

07 May 2018

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

12 Apr 2018

BRIEF-Novavax Inc Q4 Loss Per Share $0.16

* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

14 Mar 2018

BRIEF-Novavax Inc Promotes John Trizzino To CFO Role

* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER

14 Mar 2018

BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018

* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018

28 Feb 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF80.66 +2.46
Merck & Co., Inc. (MRK.N) $62.94 +0.41
Sanofi SA (SASY.PA) €72.51 --
GlaxoSmithKline plc (GSK.L) 1,563.80 +2.80
AstraZeneca plc (AZN.L) 5,606.00 +55.00

Earnings vs. Estimates